Companies › Cogent Biosciences
5 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Hematology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CGT9486 FIP1L1-PDGFRα inhibitor | PDGFRA | Phase 3 | Advanced Gastrointestinal Stromal Tumors | Jan 2030 |
| bezuclastinib KIT inhibitor | KIT | Phase 2 | Advanced Systemic Mastocytosis (AdvSM); SSM | Jul 2027 |
| CGT4859 selective FGFR2/3 inhibitor | FGFR2, FGFR3 | Phase 1 | Intrahepatic Cholangiocarcinoma (Icc) | Mar 2027 |
| CGT4255 Selective ERBB2 inhibitor | ERBB2 | Phase 1 | Advanced Solid Tumor, Adult | May 2028 |
| CGT6297 PIK3CA mutant-selective inhibitor | PIK3CA | Phase 1 | PIK3CA Mutations | Jul 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06777316 | CGT4859 | Phase 1 | Intrahepatic Cholangiocarcinoma (Icc) | Oncology | Mar 2027 |
| NCT04996875 | bezuclastinib | Phase 2 | Advanced Systemic Mastocytosis (AdvSM) | Oncology | Jul 2027 |
| NCT07361562 | CGT4255 | Phase 1 | Advanced Solid Tumor, Adult | Oncology | May 2028 |
| NCT07383506 | CGT6297 | Phase 1 | PIK3CA Mutations | Oncology | Jul 2029 |
| NCT05186753 | bezuclastinib | Phase 2 | SSM | Hematology | Jan 2030 |
| NCT05208047 | CGT9486 | Phase 3 | Advanced Gastrointestinal Stromal Tumors | Oncology | Jan 2030 |
Cash and short-term investments of $791m on 2026-09-30; operating cash outflow about $329m a year; runway about 29 months at that burn, to Feb 2029; 1 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 18 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
ORIC Pharmaceuticals Immunome ArriVent BioPharma Olema Pharmaceuticals Blueprint Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.